Etiology, clinical features and outcome of epilepsia partialis continua in cohort of 51 children.

The objective of the study was to evaluate etiology, clinical characteristics and outcome in children with epilepsia partialis continua (EPC). The investigation included 51 children with EPC aged 0.2-18 years treated in the period 1993-2009. The median period from the onset of underlying disorder to EPC was 6 months (0-72 months). EPC was caused by different pathologies: inflammatory and immune-mediated (52%), metabolic (13.7%), structural brain abnormalities (11.8%), cryptogenic (7.8%), vascular (5.9%), dual (5.9%), postoperative (2%). Median duration of EPC was 15 days (1-200 days). EPC involved more frequently the right side of the body comparing to the left one. The outcome was assessed at the end of the follow up period (mean 6.5 years, ranged 0.2-16 years). Unchanged neurological status was observed in 10 (19.6%) children, neurological consequences in 33 (64.7%) children and lethal outcome in 8 (15.7%) children. The most frequent etiology in our cohort was inflammatory and immune-mediated disease of central nerve system including Rasmussen's encephalitis. The duration of EPC was prolonged, most frequently involving the right upper limb. The outcome of EPC in children was unfavorable.
AuthorsRuzica Kravljanac, Milena Djuric, Nebojsa Jovic, Maja Djordjevic, Dragan Zamurovic, Tatjana Pekmezovic
JournalEpilepsy research (Epilepsy Res) Vol. 104 Issue 1-2 Pg. 112-7 (Mar 2013) ISSN: 1872-6844 [Electronic] Netherlands
PMID23036655 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier B.V. All rights reserved.
  • Adolescent
  • Child
  • Child, Preschool
  • Cohort Studies
  • Encephalitis (complications, diagnosis, epidemiology)
  • Epilepsia Partialis Continua (diagnosis, epidemiology, etiology)
  • Follow-Up Studies
  • Humans
  • Immune System Diseases (complications, diagnosis, epidemiology)
  • Infant
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: